New Horizons in Pharmacologic Treatment for Rheumatic Disease Pain

Rheumatic Disease Clinics of North America

Volumn 34, Issue 2, 2008, Pages 481-505

  Dray, Andy ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 4,6 DICHLORO 3 (2 OXO 1 PHENYL 3 PYRROLIDINYLIDENEMETHYL) 1H INDOLE 2 CARBOXYLIC ACID; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; CAPSAICIN; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; EPIBATIDINE; ETANERCEPT; ETHOSUXIMIDE; GABAPENTIN; HARKOSERIDE; IBUDILAST; ICATIBANT; IFENPRODIL; INFLIXIMAB; LEVACECARNINE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA CONOTOXIN MVIIA; OPIATE; PARACETAMOL; PHENACETIN; PREGABALIN; PROPENTOFYLLINE; RALFINAMIDE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRAMADOL; TRANSACIN; TRAXOPRODIL; UNINDEXED DRUG; VIMPAT;

ALLODYNIA; ARTHRALGIA; CHRONIC PAIN; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HIP OSTEOARTHRITIS; HUMAN; HYPERALGESIA; HYPERTENSION; KNEE OSTEOARTHRITIS; LOW BACK PAIN; NAUSEA; NERVE EXCITABILITY; NEUROPATHIC PAIN; NONHUMAN; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SENSITIZATION; SOMNOLENCE; SPONDYLOARTHROPATHY; STROKE; UNSPECIFIED SIDE EFFECT;

ANALGESICS; HUMANS; PAIN; RHEUMATIC DISEASES;

EID: 47049121750     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2008.04.005     Document Type: Review

References (185)

1. Dray A., and Read S.J. Future targets to control osteoarthritis pain. Arthritis Res Ther 9 (2007) 212
2. Kidd B.L., Langford R.M., and Wodehouse T. Current approaches in the treatment of arthritic pain. Arthritis Res Ther 9 (2007) 214
3. Read S.J., and Dray A. Osteoarthritic pain: a review of current, theoretical and emerging therapeutics. Expt Opin Invest Drugs 17 (2008) 616-640
4. Ruspe H. Management of chronic low back pain in 2007-2008. Curr Opin Rheumatol 20 (2008) 276-281
5. Nathan C. Points of control in inflammation. Nature 420 (2002) 846-852
6. Hunt S.P., and Mantyh P. The molecular dynamics of pain control. Nat Rev Neurosci 2 (2001) 83-91
7. Scholz J., and Woolf C.J. Can we conquer pain?. Nat Neurosci 5 (2002) 1062-1065
8. Woolf C.J., and Ma Q. Nociceptors-noxious stimulus detectors. Neuron 55 (2007) 353-364
9. Dray A. The pharmacology of inflammatory pain. In: Mersky H., Loeser J.D., and Dubner R. (Eds). The pathways of pain 1975-2005 (2005), IASP Press, Seattle (WA) 177-190
10. Scholz J., and Woolf C.J. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 10 (2007) 1361-1368
11. Hucho T., and Levine J.D. Signaling pathways in sensitization: towards a nociceptor cell biology. Neuron 55 (2007) 365-376
12. Watkins L.R., and Maier S. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 82 (2002) 981-1011
13. Ferrer-Garcia M.D., Wernicke J.F., Detke M.J., et al. The depression-pain complex: overlap between the two problems and implications for neuropathic pain. In: Campbell J.N., Basbaum A.I., Dray A., et al. (Eds). Emerging strategies for the treatment of neuropathic pain (2006), IASP Press, Seattle (WA) 307-325
14. McQuay H.J., and Moore R.A. Antidepressants and chronic pain. BMJ 314 (1997) 763-764
15. In: Campbell J.N., Basbaum A.I., Dray A., et al. (Eds). Emerging strategies for the treatment of neuropathic pain (2006), IASP Press, Seattle (WA)
16. Creamer P., Hunt M., and Dieppe P. Pain mechanisms in osteoarthritis of the knee: effect of intra-articular anaesthetic. J Rheumatol. 23 (1996) 1031-1036
17. Crawford R.W., Gie G.A., Ling R.S., et al. Diagnostic value of intra-articular anaesthetic in primary osteoarthritis of the hip. J Bone Joint Surg Br 80 (1998) 279-281
18. Kosek E., and Ordeberg G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain 88 (2000) 69-78
19. Buffington A.L., Hanlon C.A., and McKeown M.J. Acute and persistent pain modulation of attention-related anterior cingulated fMRI activations. Pain 113 (2005) 172-184
20. Rowbotham M.C., Kidd B.L., and Porreca F. Role of central sensitization in chronic pain: osteoarthritis and rheumatoid arthritis compared to neuropathic pain. In: Flor H., Kalso E., and Dostrovsky J. (Eds). Proceedings of the 11th World Congress on Pain (2006), IASP Press, Seattle (WA) 231-249
21. Baliki M.N., Gehe P.Y., Apkarain A.V., et al. Beyond feeling: chronic pain hurts the brain, disrupting the default mode network dynamics. J Neurosci 28 (2008) 1398-1403
22. Kuchinad A., Schweinhardt P., Wood P., et al. Accelerated brain gray-matter loss in fibromyalgia patients: premature aging of the brain?. J Neurosci 27 (2007) 4004-4007
23. Gu X., Yang L., and Wang S. A rat model of radicular pain induced by chronic compression of lumbar dorsal root ganglia with SURGIFLO. Anesthesiology 108 (2008) 113-121
24. Alini M., Eisenstein S.M., Ito K., et al. Are animal models useful for studying human disc disorders/degeneration?. Eur Spine J 17 (2008) 2-19
25. Le Bars D., Gozariu M., and Cadden S.W. Animal models of nociception. Pharmacol Rev 53 (2001) 597-652
26. Gold M.S., Chessell I., Devor M., et al. Peripheral nervous system targets: Rapporteur report. In: Campbell J.N., Basbaum A.I., Dray A., et al. (Eds). Emerging strategies for the treatment of neuropathic pain (2006), IASP Press, Seattle (WA) 3-36
27. Ikeda K., Cox S., and Emery P. Biological therapy in early arthritis-overtreatment or the way to go?. Arthritis Res Ther 9 (2007) 211
28. Fedmann M., and Maini R.N. Anti-TNF a therapy of rheumatoid arthritis: what we learned?. Annu Rev Immunol 19 (2001) 163-169
29. Fraenkel M., Bogardus S.T., Concato J., et al. Treatment options in knee OA. Arch Intern Med 164 (2004) 1299-1304
30. Woolf C.J., and Salter M.W. Neuronal plasticity: increasing the gain in pain. Science 288 (2000) 1765-1769
31. Gracely R.H., Lynch S.A., and Bennett G.J. Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain 51 (1992) 175-194
32. Bar K.J., Natura G., Telleria-Diaz A., et al. Changes in the effect of spinal prostaglandin E2 during inflammation: prostaglandin E9(EP1-EP4) receptors in spinal nociceptive processing of input from the normal and inflamed knee joint. J Neurosci 24 (2004) 642-651
33. Yaksh T.L., Dirig D.M., Conway C.M., et al. The acute hyperalgesic action of non-steroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 21 (2001) 5847-5853
34. Chandrasekharan N.V., Dai H., Roos K.L., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci 99 (2002) 13926-13931
35. Mitchell J.A., and Warner T.D. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 5 (2006) 75-85
36. Jakobsson P.J., Thoen S., Morgenstern R., et al. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci 96 (1999) 7220-7225
37. Claveau D., Sirinyan M., Guay J., et al. Microsomal prostaglandin synnthase-1 is a major terminal synthase that is selectively upregulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-arthritis model. J Immunol 170 (2003) 4738-4744
38. Trebino C.E., Stock J.L., Gibbons C.P., et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci 100 (2003) 9044-9049
39. Dray A. Kinins and their receptors in hyperalgesia. Can J Physiol Pharmacol 75 (1997) 704-712
40. Dray A., and Perkins M.N. Bradykinin and inflammatory pain. Trends Neurosci 16 (1993) 99-104
41. Wotherspoon G., and Winter J. Bradykinin B1 receptor is constitutively expressed in the rat sensory nervous system. Neurosci Lett 294 (2000) 175-178
42. Shughrue P.J., Ky B., and Austin C.P. Localization of B1 bradykinin receptors mRNA in the primate brain and spinal cord: an in situ hybridization study. J Comp Neurol 46 (2003) 372-384
43. Levy D., and Zochodne D.W. Increased mRNA expression of the B1 and B2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain. Pain 86 (2000) 265-271
44. Fox A., Wotherspoon G., McNair K., et al. Regulation and function of spinal and peripheral neuronal B(1) bradykinin receptors in inflammatory mechanical hyperalgesia. Pain 104 (2003) 683-691
45. Ferreira J., Beirith A., Mori M.A.S., et al. Reduced nerve injury induced neuropathic pain in kinin B1 receptor knock-out mice. J Neurosci 25 (2005) 2405-2412
46. Eisenbarth H., Rukwied R., Petersen M., et al. Sensitization to bradykinin B1 and B2 receptor activation in UV-B irradiated human skin. Pain 110 (2004) 197-204
47. Vellani V., Zachrisson O., and McNaughton P.A. Functional bradykinin B1 receptors are expressed in nociceptive neurons and are upregulated by the neurotrophin GDNF. J Physiol 560 (2004) 391-401
48. Marceau F., Hess J.F., and Bachvarov D.R. The B1 receptors for kinins. Pharmacol Rev 50 (1998) 357-386
49. Liang Y.F., Haake B., and Reeh P.W. Sustained sensitization and recruitment of rat cutaneous nociceptors by bradykinin and a novel theory of its excitatory action. J Physiol 532 (2001) 229-239
50. Fox A., Kaur S., Li B., et al. Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor. Br J Pharmacol 144 (2005) 889-899
51. Stewart J.M. Bradykinin antagonists: discovery and development. Peptides 25 (2004) 527-732
52. Burgess G.M., Perkins M.N., Rang H.P., et al. Bradyzide, a potent nonpeptide B2 bradykinin receptors antagonist with long lasting oral activity in animal models of inflammatory hyperalgesia. Br J Pharmacol 129 (2000) 77-86
53. Gougat J., Ferrari B., Lionel S., et al. SSR240612 [(2R)-2-[((3R0-3-(1,3-benzodiol-5-yl)-3-{[(6-methoxy-2-napthyl)sulfonyl]amino}propanoyl)amino]-3-(4-{[2R,6S)-2,6-dimethylpiperidyl] methyl} phenyl} -N-isoproyl-Nmethylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 309 (2005) 661-669
54. Gabra B.H., and Sirois P. Beneficial effects of chronic treatment with the selective bradykinin B1 receptor antagonists, R-715 and R-953, in attenuating streptozotocin-diabetic thermal hyperalgesia. Peptides 24 (2003) 1131-1139
55. Flechtenmacher J., Talke M., Veith D., et al. Icatibant induces pain relief in patients with osteoarthritis of the knee. Proceedings of the 9th World Congress on Osteoarthritis (ORSI). Osteo Arthritis Res Soc Int 12 (2004) P332
56. Sommer C., and Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 361 1-3 (2004) 184-187
57. Ohtori S., Takahashi K., Moriya H., et al. TNF-alpha and TNF-alpha receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies in murine DRG and spinal cord. Spine 29 (2004) 1082-1088
58. Pollock J., McFarlane S.M., Connell M.C., et al. TNF-alpha receptors simultaneously activate Ca2+ mobilisation and stress kinases in cultured sensory neurons. Neuropharmacology 42 (2002) 93-106
59. Schafers M., Marziniak M., Sorkin L.S., et al. Cyclooxygenase inhibition in nerve-injury and TNF-induced hyperalgesia in the rat. Exp Neurol 185 1 (2004) 160-168
60. Schafers M., Sorkin L.S., Geis C., et al. Spinal ligation induces transient upregulation of tumor necrosis factor receptors 1 and 2 in injured and adjacent uninjured dorsal root ganglia of rat. Neurosci Lett 347 (2003) 179-182
61. Grunke M., and Schulze-Koops H. Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade. Ann Rheum Dis 65 (2006) 555-556
62. Nobuhisa S., Kikuchi S.-I., Konno S.-I., et al. Anti-TNF-[alpha] antibody reduces pain behavioral changes induced by epidural application of nucleus pulposus in a rat model depending on the timing of administration. Spine 32 (2007) 413-416
63. Kotani N., Kudo R., Sakurai Y., et al. Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia. Am J Med 116 (2004) 318-324
64. Lindenlaub T., and Sommer C. Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol 105 (2003) 593-602
65. Zhang N., Inan S., Cowan A., et al. A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci 102 (2005) 4536-4541
66. Oh S.B., Tran P.B., Gillard S.E., et al. Chemokines and glycoprotein 120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 21 (2001) 5027-5035
67. Abbadie C., Lindia J.A., Cumiskey A.M., et al. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci 100 (2003) 7947-7952
68. Moore K.A., Kohno T., Karchewski L.A., et al. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci 22 (2002) 6724-6731
69. Watkins L.R., and Maier S.F. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2 (2003) 973-985
70. White F.A., Jung H., and Miller R. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci U S A 104 (2007) 20151-20158
71. Sweitzer S.M., Pahl J.L., and DeLeo J.A. Propentofylline attenuates vincristine-induced peripheral neuropathy in the rat. Neurosci Lett 400 (2006) 258-261
72. Ledeboer A., Liu T., Shumilla J.A., et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol 10 (2007) 1-13
73. Raghavendra V., Tanga F., Rutkowski M.D., et al. Anti-hyperalgesic and morphine-sparing actions pf propentofylline following peripheral nerve injury in rats: mechanistic implications of spinal glia and proinflammatory cytokines. Pain 104 (2003) 655-664
74. Donelly-Roberts D., McGaraughty S., Shieh C.C., et al. Painful purinergic receptors. J Pharmacol Exp Ther 324 (2008) 409-415
75. Chessell I.P., Hatcher J.P., Davey P.T., et al. Disruption of the P2x7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Nature 114 (2005) 386-396
76. Tsuda M., Shigemoto-Mogami Y., Koizumi S., et al. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 424 (2003) 778-783
77. Milligan E.D., Langer S.J., Sloane E.M., et al. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci 21 (2005) 2136-2148
78. Giatromanolaki A., Sivridis E., Maltezos E., et al. Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 5 4 (2003) R193-R201
79. Leffler A., Monter B., and Koltzenburg M. The role of the capsaicin receptor TRPV1 and acid sensing ion channels (ASICs) in proton sensitivity of subpopulation of primary nociceptive neurons in rats and mice. Neuroscience 139 (2006) 699-709
80. Dube G.R., Lehto S.G., Breese N.M., et al. Electrophysiological and in vivo characterization of A-317567, a novel blocker of acid sensing ion channels. Pain 117 (2005) 88-96
81. Eglen R.M., Hunter J.C., and Dray A. Ions in the fire: recent ion-channel research and approaches to pain therapy. Trends Pharmacol Sci 8 (1999) 337-342
82. Matzner O., and Devor M. Hyperexcitability at sites of nerve injury depends on voltage sensitive - sodium channels. J Neurophysiol 72 (1994) 349-359
83. Devor M. Sodium channels and mechanisms of neuropathic pain. Pain 7 Suppl 1 (2005) S3-S12
84. Amir R., Liu C.N., and Devor M. Oscillatory mechanisms in primary sensory neurones. Brain 125 (2002) 421-435
85. Waxman S.G., and Dib-Hajj S. Erythermalgia: molecular basis for an inherited pain syndrome. Trends Mol Med 11 (2005) 555-562
86. v1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci U S A 101 (2004) 12706-12711
87. Coward K., Plumpton C., Facer P., et al. Immunolocalization of SNS/PN3 and NaN/SNS2 sodium channels in human pain states. Pain 85 (2000) 41-50
88. Hains B.C., Klein J.P., Saab C.Y., et al. Upregulation of sodium channel NaV 1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J Neurosci 23 (2003) 8881-8892
89. Roza C., Laird J.M., Souslova V., et al. The tetrodotoxin-resistant Na channel NaV1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J Physiol 550 3 (2003) 921-926
90. Jarvis M.F., Honore P., Shieh C.C., et al. A-803467 a potent and selelctive NaV1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci U S A 104 (2007) 8520-8525
91. Beyreuther B., Callizot N., and Stohr T. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol 539 (2006) 64-70
92. Hao J.X., Stohr T., Selve N., et al. Lacosamide, a new anti-epileptic, alleviates neuropathic pain-like behaviors in rat models of spinal cord or trigeminal nerve injury. Eur J Pharmacol 553 (2006) 135-140
93. Cattabeni F. Ralfinamide. Newron Pharamaceuticals. I Drugs 7 (2004) 935-939
94. Yaksh T.L. Calcium channels as therapeutic targets in neuropathic pain. Pain 7 Suppl 1 (2006) S13-S30
95. Saegusa H., Kurihara T., et al. Suppression of inflammation and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. EMBO J 20 (2001) 2349-2356
96. Miljanich G.P. Ziconitide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 11 (2004) 3029-3040
97. Snutch T.P. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx 2 (2005) 662-670
98. Kim C., Jun K., Lee T., et al. Altered nociceptive responses in mice deficient in the alpha1δ subunit of the voltage dependent calcium channel. Mol Cell Neurosci 18 (2001) 235-245
99. Luo Z.D., Calcutt N.A., Higuera E.S., et al. Injury type-specific calcium channel alpha (2) delta-1 subunit up-regulation in rat neuropathic pain. J Pharmacol Exp Ther 303 (2002) 1199-1205
100. Hendrich J., Van Winh A.T., Heblich F., et al. Pharmacological disruption of calcium channel trafficking by the alpha2 delta ligand gabapentin. Proc Natl Acad Sci U S A 105 (2008) 3628-3633
101. Ikeda H., Heinke B., Ruscheweyh R., et al. Synaptic plasticity in spinal lamina 1 projection neurons that mediate hyperalgesia. Science 299 (2003) 1237-1240
102. Matthews E.A., and Dickenson A.H. Effects of spinally delivered N-and P-type voltage dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Eur J Pharmacol 415 (2001) 141-149
103. Flatters S.J., and Bennett G.J. Ethosuximaide reverses paclitaxel and vincristine-induced painful peripheral neuropathy. Pain 109 (2004) 150-161
104. Ramsey I.S., Delling M., and Clapham D.E. An introduction to TRP channels. Annu Rev Physiol 68 (2006) 619-647
105. Vellani V., Mappleback S., Moriondo A., et al. Protein kinase C activation gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J Physiol 534 (2001) 813-825
106. Szallasi A., and Blumberg P.M. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 51 2 (1999) 159-212
107. Bley K.R. Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin Investig Drugs 13 (2004) 1445-1456
108. Gavva N.R., Tamir R., Qu Y., et al. AMG 9810 [(E) -3- (4-t- butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 313 (2005) 473-484
109. Wang H.L., Katon J., Balan C., et al. Vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties. J Med Chem 50 (2007) 3528-3539
110. Garcia-Martinez C., Humet M., Planells-Casas R., et al. Attenuation of thermal nociception and hyperalgesia by VR1 blockers. Proc Natl Acad Sci U S A 99 (2002) 2374-2379
111. Chizh B.A., O'Donnell M.B., Napoltano A., et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 132 (2007) 132-141
112. Gavva N.R., Bannon A.W., Howland D.N., et al. Repeated administration of vanilloid receptor TRPV1 antagonist attenuates hyperthermia elicited by TRPV1 blockade. J Pharmacol Exp Ther 323 (2007) 128-137
113. Gavva N.R., Treanor J.S., Garami A., et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 136 (2008) 202-210
114. Bandell M., Story G.M., Hwang S.W., et al. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 41 (2004) 849-853
115. Obata K., Katsura H., Mizushima T., et al. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. J Clin Invest 115 (2005) 2393-2401
116. Proudfoot C.J., Garry E.M., Cottrell D.F., et al. Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr Biol 16 (2006) 1591-1609
117. McNamara C.R., Mandel-Brehm J., Bautista D.M., et al. TRPA1 mediates formalin-induced pain. Proc Natl Acad Sci U S A 104 (2007) 13525-13530
118. 2+ waves in keratinocytes are transmitted to sensory neurons: the involvement of extracellular ATP and P2Y2 receptor activation. Biochem J 380 (2004) 329-338
119. Peier A.M., Reeve A.T., Andersson D.A., et al. A heat sensitive TRP channel expressed in keratinocytes. Science 296 (2002) 2046-2049
120. Decker M.W., Meyer M.D., and Sullivan J.P. The therapeutic potential of nicotinic acetylcholine receptor agonist for pain control. Expert Opin Investig Drugs 10 (2001) 1819-1830
121. Vincler M. Neuronal nicotinic receptors as targets for novel analgesics. Expert Opin Investig Drugs 14 (2005) 1191-1198
122. Meyer M.D. Neuronal nicotinic acetylcholine receptors as a target for the treatment of neuropathic pain. Drug Devolpment Research 67 (2006) 355-359
123. Neugebauer V. Glutamate receptor ligands. Handb Exp Pharmacol 177 (2007) 217-249
124. Szekely J.I., Torok K., and Mate G. The role of ionotropic glutamate receptors in nociception with special regard to the AMPA binding sites. Curr Pharm Des 8 10 (2002) 887-912
125. Sang C.N., Hostetter M.P., Gracely R.H., et al. AMPA/Kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology 89 (1998) 1060-1067
126. Sang C.N., Ramadan N.M., Wallihan R.G., et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 24 (2004) 596-602
127. Olney J.W., and Farber N.B. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13 (1995) 335-345
128. Danysz W., and Parsons C.G. GlycineB recognition site of NMDA receptors and its antagonists. Amino Acids 14 (1998) 205-206
129. Quartaroli M., Fasdelli N., Bettelini L., et al. GV196771A, an NMDA receptor/glycine site antagonist, attenuates mechanical allodynia in neuropathic rats and reduces tolerance induced by morphine in mice. Eur J Pharmacol 430 (2001) 219-227
130. Wallace M.S., Rowbotham M.C., Katz N.P., et al. A randomized, double blind, placebo-controlled trial of a glycine antagonist in neuropathic pain. Neurology 59 (2002) 1694-1700
131. Gogas K.R. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 6 (2006) 68-74
132. Hudson L.J., Bevan S., McNair K., et al. Metabotropic glutamate receptor 5 up-regulation in A-fibers after spinal nerve injury: 2-Methyl-6-(phenylethynyl)-pyridine (MPEP) reverses the induced thermal hyperalgesia. J Neurosci 22 (2002) 2660-2668
133. Zhu C.Z., Wilson S.G., Mikusa J.P., et al. Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol 506 (2004) 107-118
134. Taniguchi K., Shinjo K., Mizutani M., et al. Antinociceptive actions of CP-101, 606, an NMDA receptor NR2B subunit antagonist. Br J Pharmacol 12 (1997) 809-812
135. Dogrul A., Ossipov M.H., Lai J., et al. Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGluR5) antagonist, in experimental neuropathic pain in rats. Neurosci Lett 292 (2000) 115-118
136. Jaeschke G., Wettstein J.G., Nordquist R.E., et al. mGlu5 receptor antagonists and their therapeutic potential. Expert Opinion Therapeutic Patents 18 (2008) 123-142
137. Yaksh T.L. Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiol Scand 41 (1997) 94-111
138. Hurley R.W., and Hammond D.L. The analgesic effects of supraspinal μ and δ opioid receptor agonists are potentiated during persistent inflammation. J Neurosci 20 (2000) 1249-1259
139. Sawynok J. Topical and peripherally acting analgesics. Pharmacol Rev 55 (2003) 1-20
140. Likar R., Schafer M., Paulak F., et al. Intraarticular morphine analgesia in chronic pain patients with osteoarthritis. Anesth Analg 84 (1997) 1313-1317
141. Menendez L., Lastra A., Meana A., et al. Analgesic effects of loperamide in bone cancer pain in mice. Pharmacol Biochem Behav 81 (2005) 114-21
142. Whiteside G.T., Boulet J.M., and Walker K. The role of central and peripheral mu opioid receptors in inflammatory pain and edema: a study using morphine and DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid). J Pharmacol Exp Ther 314 (2005) 1234-1240
143. Valenzano K.J., Miller W., Chen Z., et al. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza spiro[4.5]dec-3-yl]-acetic acid), a peripherally-acting mu opioid agonist with anti-hyperalgesic properties. J Pharmacol Exp Ther 310 (2004) 783-729
144. Dray A. Alternatives to mu-opioid analgesics: delta-opioid and galanin-receptor selective compounds. In: Kalso E., McQuay H.J., and Wiesenfeld-Hallin Z. (Eds). Progress in pain research and management (1999), IASP Press, Seattle (WA) 269-280
145. Cahill C.M., Morinville A., Lee M.-C., et al. Prolonged morphine treatment targets δ-opioid receptors to neuronal plasma membranes and enhances δ-mediated antinociception. J Neurosci 21 (2001) 7598-7607
146. Fox A., and Bevan S. Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin Investig Drugs 14 (2005) 695-703
147. Campbell F.A., Tramer M.R., Carroll D., et al. Are cannabinoids an effective and safe treatment option in the management of pain? A quantitative systematic review. BMJ 323 (2001) 13-16
148. Agarwal N., Pacher P., Tegeder I., et al. Cannabinoid mediated analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 7 (2007) 870-879
149. Dyson A., Peacock M., Chen A., et al. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 116 (2005) 129-137
150. Richardson J.D., Kilo S., and Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interactions with peripheral CB1 receptors. Pain 75 (1998) 111-119
151. Karst M., Salim K., Burstein S., et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290 (2003) 1757-1762
152. Labuda C.J., Koblish M., and Little P.J. Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur J Pharmacol 527 (2005) 172-175
153. Malan Jr. T.P., Ibrahim M.M., Lai J., et al. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects?. Curr Opin Pharmacol 3 1 (2003) 62-67
154. Valenzano K.J., Tafesse L., Lee G., et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist GW405833,utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48 (2005) 658-672
155. Sokal D.M., Elmes S.J.R., Kendall D.A., et al. Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurons via activation of CB2 receptors in anaesthetized rats. Neuropharmacology 45 (2003) 404-411
156. Zhang J., Hoffert C., Vu K., et al. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17 (2003) 2750-2754
157. Cravatt B.F., and Lichtman A.H. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 61 (2004) 149-160
158. Cravatt B.F., Demarest K., Patricelli M.P., et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolyse. Proc Natl Acad Sci 98 (2001) 9371-9376
159. Lichtman A.H., Leung D., Shelton C.C., et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311 (2004) 441-448
160. Sato J., and Perl E.R. Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. Science 251 (1991) 1608-1610
161. Lee D.H., Liu X., Kim H.T., et al. Receptor subtype mediating the adrenergic sensitivity of pain behavior and ectopic discharges in neuropathic Lewis rats. J Neurophysiol 81 (1999) 2226-2233
162. Sundrup S.H., Otto M., Finnerup N.B., et al. Antidepressants in the treatment of neuropathic pain Basic Clin Pharmacol. Toxicol 96 (2005) 399-409
163. Griffin J.W. The roles of growth factors in painful length-dependent axonal neuropathies. In: Campbell J.N., Basbaum A.I., and Dray A. (Eds). Emerging strategies for the treatment of neuropathic pain (2006), IASP Press, Seattle (WA) 271-290
164. Zweifel L.S., Kuruvilla R., and Ginty D.D. Functions and mechanisms of retrograde neurotrophin signaling. Nat Rev Neurosci 6 (2005) 615-625
165. Lu B., Pang P.T., and Woo N.H. The yin and yang of neurotrophin action. Nat Rev Neurosci 6 (2005) 603-614
166. Hefti F.F., Rosenthal A., Walicka P.A., et al. Novel class of pain drug based on antagonism of NGF. Trends in Pharmacological Sciences 27 (2005) 85-91
167. Theodosiou M., Rush R.A., Zhou X.F., et al. Hyperalgesia due to nerve damage: role of nerve growth factor. Pain 81 (1999) 245-255
168. Ro L.S., Chen S.T., Tang L.M., et al. Effect of NGF and anti-NGF on neuropathic pain in rats following chronic constriction injury of the sciatic nerve. Pain 79 (1999) 265-274
169. Fjell J., Cummings T.R., Fried K., et al. In vivo NGF deprivation reduces SNS expression and TTX-R sodium currents in IB4-negative DRG neurons. J Neurophysiol 81 (1999) 803-810
170. Ji R.R., Samad T.A., Jin S.X., et al. P38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36 (2002) 57-68
171. Mamet J., Lazdunski M., and Voilley N. How nerve growth factor drives physiological and inflammatory expression of acid-sensing ion channels 3 in sensory neurons. J Biol Chem 278 (2003) 48907-48913
172. Ramer M.S., Bradbury E.J., and McMahon S.B. Nerve growth factor induces P2X(3) expression in sensory neurons. J Neurochem 77 (2001) 864-875
173. Halliday D.A., Zettler C., Rush R.A., et al. Elevated growth factor levels in the synovial fluid of patients with inflammatory joint disease. Neurochem Res 23 (1998) 919-922
174. Discou E., Perrot S., Menkes C.J., et al. Nerve growth factor (NGF) Autoantibodies and NGF in the synovial fluid: Implications in spondylarthropathies. Autoimmunity 24 (1996) 1-9
175. Sarchielli P., Alberti A., Floridi A., et al. Levels of nerve growth factor in cerebrospinal fluid of chronic headache patients. Neurology 57 (2001) 132-134
176. Andreev N., Dimitrieva N., Kolzenburg M., et al. Peripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympathetic post-ganglionic neurones. Pain 63 (1995) 109-115
177. Svensson P., Cairns B., Wang K., et al. Injection of nerve growth factor into human masseter muscle evokes long-lasting mechaniscal allodynia and hyperalgesia. Pain 104 (2003) 241-247
178. Colquhoun A., Lawrance G.M., Shamovsky I.L., et al. Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-(benzoylamino)-4,9-dihydro-4methyl-8-oxo-pyrazolo-[5,1-b]-quinazoline-2-carboxylic acid] suggest altered NGF-p75NTR interactions in the presence of trkA. J Pharmacol Exp Ther 310 (2004) 505-511
179. Owolabi J.B., Rizkalla G., Tehim A., et al. Characterization of antiallodynic actions ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. J Pharmacol Exp Ther 289 (1999) 1271-1276
180. Lane N., Webster L., Shiao-Ping L., et al. RN624 (Anti NGF) improves pain and function in subjects with moderate knee osteoarthritis: a phase 1 study. Arthritis Rheum 52 (2005) S461
181. Sah D.W., Ossipov M.H., and Porecca F. Neurotrophic factors as novel therapeutics for neuropathic pain. Nat Rev Drug Discov 2 (2003) 460-472
182. Kerr B.J., Bradbury E.J., Bennett D.L., et al. Brain derived neurotrophic factor modulates nociceptive sensory neurone input and NMDA-evoked responses in the rat spinal cord. J Neurosci 19 (1999) 5136-5149
183. Deng Y.S., Zhong J.H., and Zhou X.F. Effects of endogenous neurotrophin on sympathetic sprouting in the dorsal root ganglia and allodynia following spinal nerve injury. Exp Neurol 164 (2000) 344-350
184. Wang R., King T., Ossipov M.H., et al. Restoration of sensory function by immediate or delayed systemic artemin after dorsal root injury. Nat Neurosci 11 (2008) 488-496
185. Nutt J.G., Burchiel K.J., Comella C.L., et al., ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60 (2003) 69-73